SecBot SecBot

CRIS

CURIS INC
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001108205 Biotech & Drug Discovery
$0.4400 −0.01 (−2.22%)
Nov 16 4:00 PM ET · prev $0.4500
Market cap
$4.2M
Nano cap
Consensus
Buy
89% Buy or better · 9 analysts
Median target
$20.00
+4445% · range $6.00–65.00
1 year
−98.2%
from $24.60 · Nov 17
30 days
+15.8%
from $0.3800
52-week range
$0.3800–27.40
−98% from high · low Oct 19
Avg volume 20D
12.21M
Nov 4 spike 163.53M
Short interest
1.03M
≈15.4% of shares · +134.3%
Days to cover
1.1
at average volume
Insider net
+$5.5K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read BEARISH 11 reports · 90 days
Balance 5 bearish · 0 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 10/11

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $5.5K. No open-market sales.

  • InstitutionsMIXED

    Q2 2026: 4 added (0 new), 3 trimmed or exited.

  • AnalystsBULLISH

    8 of 9 rate it Buy or better. Every target is above the price.

  • Short sellersBUILDING

    Short interest +134.3% to 1.03M shares. 1.1 days to cover, ≈15.4% of shares.

  • TrendRANGE

    41% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 5.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYADD504,292$263.3K
GEODE CAPITAL MANAGEMENT, LLCADD293,097$153.0K
RENAISSANCE TECHNOLOGIES LLCTRIM141,972$74.1K
NORTHERN TRUST CORPDOUBLED95,870$50.1K
LPL Financial LLCTRIM14,977$7.8K
OSAIC HOLDINGS, INC.DOUBLED1,510$785.00
UBS Group AGTRIM46$24.00
RENAISSANCE TECHNOLOGIES LLCADD366,740$200.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 89% rate it Buy or better
Strong Buy2Buy6Hold1Sell0Strong Sell0
12-month targets · 3 analysts

Price is below the lowest target. Median implies +4445%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 13, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 17, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jul 24, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Reddit Mentions per day, 14 days
Recent posts
All social signals and their track records

Insider ledger

Form 4
$5.5K
bought · 1 insider
$0
sold · 0 insiders
DateInsiderTypeValue
Jul 7, 2026
GREENACRE MARTYN D
Director
Jul 7, 2026
AWARD$36.0K
Jul 7, 2026
KAITIN KENNETH I
Director
Jul 7, 2026
AWARD$36.0K
Jul 7, 2026
Rubin Marc
Director
Jul 7, 2026
AWARD$36.0K
Jul 7, 2026
Zung Jonathan B.
CDO
Jul 7, 2026
AWARD$255.4K
Jul 7, 2026
Hohneker John
Director
Jul 7, 2026
AWARD$36.0K
Jul 7, 2026
Duvall Diantha
CFO
Jul 7, 2026
AWARD$255.4K
Jul 7, 2026
Dentzer James E
President & CEO
Jul 7, 2026
AWARD$582.4K
Jul 7, 2026
Borgman Anne Elizabeth
Director
Jul 7, 2026
AWARD$36.0K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next QNoneNoneNo data$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
1,029,348
shares short
+134.3%
vs prior settlement
1.1
days to cover
≈15.4%
of shares outstanding
On the Reg SHO threshold listsince Nov 2, 2026: persistent fails-to-deliver. View list
Trading halts
Nov 4, 2026Volatility PauseResumed
Nov 4, 2026Volatility PauseResumed
Nov 4, 2026Volatility PauseResumed
Nov 3, 2026Volatility PauseResumed
Nov 3, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 SEC
Nantahala Capital Management filed an amended Schedule 13G disclosing beneficial ownership of 258,739 shares (9.99% of…
SC 13G/A · Impact 3/10
Nov 13, 2026 SEC
Nantahala Capital Partners filed an amended Schedule 13G disclosing beneficial ownership of 108,143 shares (4.328% of…
SC 13G/A · Impact 2/10
Nov 12, 2026 Earnings
Curis Provides Third Quarter 2026 Business Update
Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., Nov. 12, 2026
Oct 16, 2026 Press
Curis announced an $8.5 million private placement with existing healthcare-focused institutional investors, selling…
Impact 6/10
Jul 7, 2026 Insider
GREENACRE MARTYN D was granted 6,800 shares
Director @ $5.29 ($36.0K)
Jul 7, 2026 Insider
KAITIN KENNETH I was granted 6,800 shares
Director @ $5.29 ($36.0K)
Jul 7, 2026 Insider
Rubin Marc was granted 6,800 shares
Director @ $5.29 ($36.0K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent

SecBot reports

17 filings · 1 press release · 1 bullish · 8 bearish · 8 neutral
All CRIS filing & press-release reports (18)